Hrair Darakjian
Orthopedic Surgery · Valencia, CANPI 1447274972
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $853 of the $1,278 with a category attached, or 66.8%. 16 manufacturers reported payments, led by Biofire Diagnostics, LLC at 33.2% of the total. Reporting peaked in 2020 at $560 and has fallen 81.2% since, to $105 in 2024.
Across 41 payments — averaging $31.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biofire Diagnostics, LLC$425
- Amgen$148
- Forte Bio-pharma LLC$140
- Johnson & Johnson$106
- Kowa Pharmaceuticals America, Inc.$96
- Arbor Pharmaceuticals, Inc.$58
- plus $306 from 10 others
What the payments were for
- Speaking & faculty fees$42533%
- Food & beverage$85367%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biofire Diagnostics, LLC | 1 | $425 |
| Amgen | 9 | $148 |
| Forte Bio-pharma LLC | 3 | $140 |
| Johnson & Johnson | 5 | $106 |
| Kowa Pharmaceuticals America, Inc. | 4 | $96 |
| Arbor Pharmaceuticals, Inc. | 3 | $58 |
| IBSA Pharma Inc. | 3 | $48 |
| Tersera Therapeutics LLC | 2 | $42 |
| Convatec Inc. | 2 | $37 |
| Stryker | 1 | $36 |
| Fidia Pharma USA Inc. | 2 | $33 |
| Biogen | 1 | $30 |
| Zyla Life Sciences, Inc. | 2 | $24 |
| Novo Nordisk | 1 | $20 |
| Collegium Pharmaceutical, Inc. | 1 | $20 |
| Orthofix Medical, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,278 in reported general payments places this provider in the 60th percentile of 130 orthopedic surgery providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 963 | $23,903 |
| Diclofenac Sodium | 238 | $18,512 |
| BelbucaBuprenorphine Hcl | 13 | $8,208 |
| Cyclobenzaprine Hcl ErCyclobenzaprine Hcl | 16 | $7,132 |
| Diclofenac Epolamine | 12 | $6,714 |
| Gabapentin | 662 | $5,026 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 144 | $3,474 |
| Ibuprofen-FamotidineIbuprofen/Famotidine | 16 | $3,179 |
| Lidocaine | 19 | $2,617 |
| Celecoxib | 53 | $2,288 |
| Tramadol Hcl | 373 | $1,971 |
| Oxycodone Hcl | 50 | $1,534 |
| Carisoprodol | 183 | $1,343 |
| Meloxicam | 435 | $1,268 |
| Ibuprofen | 156 | $780 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Belbuca | $20 | $8,20813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 130 orthopedic surgery providers in California.
Other orthopedic surgery in Valencia
- Tarek BittarValencia$2K
- Marshall ChingOroville$17.8M
- Ran SchwarzkopfOrange$2M
- Brian ChingOroville$1.4M
- Peter KurzweilLong Beach$494K
- Scott Hackerla Mesa$434K
- Richard NussbaumSherman Oaks$238K
- William KimTorrance$164K
- Peter BordenTorrance$111K
- Raymond FolmarIrvine$70K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.